Date: 2015-05-06
Type of information: IPO
Company: Atyr Pharma (USA - CA)
Investors:
Amount:
Funding type: IPO
Planned used:
Others: * On May 6, 2015, aTyr Pharma announced the pricing of its initial public offering of 5,360,000 shares of its common stock at an initial public offering price of $14.00 per share. In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 804,000 shares of common stock from aTyr at the initial public offering price, less underwriting discounts and commissions. aTyr’s common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol “LIFE” on May 7, 2015. Closing of the offering is expected to occur on or about May 12, 2015, subject to customary closing conditions. J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering. BMO Capital Markets Corp. is acting as lead manager and William Blair & Company, L.L.C. is acting as co-manager. * On April 6, 2015, aTyr Pharma announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. aTyr Pharma intends to apply to list its common stock on The NASDAQ Global Market under the symbol “LIFE”. J.P. Morgan Securities LLC, and Citigroup, Inc. will act as lead book-running managers for the offering. BMO Capital Markets and William Blair and Company, LLC will act as a co-managers.
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases
